2023
Chronic GCPII (glutamate‐carboxypeptidase‐II) inhibition reduces pT217Tau levels in the entorhinal and dorsolateral prefrontal cortices of aged macaques
Bathla S, Datta D, Liang F, Barthelemy N, Wiseman R, Slusher B, Asher J, Zeiss C, Ekanayake‐Alper D, Holden D, Terwilliger G, Duque A, Arellano J, van Dyck C, Bateman R, Xie Z, Nairn A, Arnsten A. Chronic GCPII (glutamate‐carboxypeptidase‐II) inhibition reduces pT217Tau levels in the entorhinal and dorsolateral prefrontal cortices of aged macaques. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2023, 9: e12431. PMID: 37915375, PMCID: PMC10617575, DOI: 10.1002/trc2.12431.Peer-Reviewed Original ResearchSporadic Alzheimer's diseaseEntorhinal cortexGCPII inhibitionDorsolateral prefrontal cortexChronic inhibitionTau pathologyTau hyperphosphorylationAged macaquesType 3 metabotropic glutamate receptorAlzheimer's diseasePrefrontal cortexRhesus macaquesVehicle-treated monkeysAged rhesus macaquesMetabotropic glutamate receptorsApparent side effectsAmyloid beta 1Regulation of calciumGCPII inhibitorsKey etiological factorGCPII activityPrimate dlPFCNeuronal damageCSF analysisCalcium dysregulation
2020
The MARBLE Study Protocol: Modulating ApoE Signaling to Reduce Brain Inflammation, DeLirium, and PostopErative Cognitive Dysfunction
VanDusen K, Eleswarpu S, Moretti E, Devinney M, Crabtree D, Laskowitz D, Woldorff M, Roberts K, Whittle J, Browndyke J, Cooter M, Rockhold F, Anakwenze O, Bolognesi M, Easley M, Ferrandino M, Jiranek W, Berger M, Adams S, Amundsen C, Avasarala P, Barber M, Berchuck A, Blazer III D, Brassard R, Brigman B, Cai V, Christensen S, Cox M, Davidson B, DeOrio J, Erdmann D, Erickson M, Funk B, Gadsden J, Gage M, Gingrich J, Greenup R, Ha C, Habib A, Abi Hachem R, Hall A, Hartwig M, Havrilesky L, Heflin M, Holland C, Hollenbeck S, Hopkins T, Inman B, Jang D, Kahmke R, Karikari I, Kawasaki A, Klapper J, Klifto C, Klinger R, Knechtle S, Lagoo-Deenadayalan S, Lee W, Levinson H, Lewis B, Lidsky M, Lipkin M, Mantyh C, McDonald S, Migaly J, Miller T, Mithani S, Mosca P, Moul J, Novick T, Olson S, Pappas T, Park J, Peterson A, Phillips B, Polascik T, Potash P, Preminger G, Previs R, Robertson C, Scales Jr C, Shah K, Scheri R, Siddiqui N, Smani S, Southerland K, Stang M, Syed A, Szydlowska A, Thacker J, Terrando N, Toulgoat-DuBois Y, Visco A, Weidner A, Yanamadala M, Zani Jr S. The MARBLE Study Protocol: Modulating ApoE Signaling to Reduce Brain Inflammation, DeLirium, and PostopErative Cognitive Dysfunction. Journal Of Alzheimer’s Disease 2020, 75: 1319-1328. PMID: 32417770, PMCID: PMC7923142, DOI: 10.3233/jad-191185.Peer-Reviewed Original ResearchConceptsPerioperative neurocognitive disordersAdverse event ratesCN-105Placebo-treated patientsDose-escalation trialPerioperative adverse event ratesEvent ratesPostoperative cognitive testingOlder surgical patientsPostoperative cognitive dysfunctionRandomized to controlPostoperative neuroinflammationEscalation trialNon-neurological surgeryReduced brain inflammationNon-cardiacPerioperative administrationPreventing PNDChart reviewSurgical patientsLong-term cognitive declineCSF analysisBrain inflammationRisk factorsSurgery
2012
The cerebrospinal fluid proteome in HIV infection: change associated with disease severity
Angel TE, Jacobs JM, Spudich SS, Gritsenko MA, Fuchs D, Liegler T, Zetterberg H, Camp DG, Price RW, Smith RD. The cerebrospinal fluid proteome in HIV infection: change associated with disease severity. Clinical Proteomics 2012, 9: 3. PMID: 22433316, PMCID: PMC3353874, DOI: 10.1186/1559-0275-9-3.Peer-Reviewed Original ResearchCNS HIV infectionHIV infectionCerebrospinal fluidChronic asymptomatic infectionSystemic HIV infectionNervous system infectionAmyloid precursor proteinCSF proteomic analysisCerebrospinal fluid proteomeCSF neopterinAntiretroviral therapyDifferent time pointsSystem infectionNeural injuryImmune activationMotor dysfunctionAsymptomatic infectionClinical spectrumCSF biomarkersCSF analysisDisease progressionCSF samplesNeuronal plasticityDisease severityInfection
2009
Unusual presentations of nervous system infection by Cryptococcus neoformans
Searls D, Sico JJ, Omay S, Bannykh S, Kuohung V, Baehring J. Unusual presentations of nervous system infection by Cryptococcus neoformans. Clinical Neurology And Neurosurgery 2009, 111: 638-642. PMID: 19541406, DOI: 10.1016/j.clineuro.2009.05.007.Peer-Reviewed Original ResearchConceptsNervous system infectionHuman immunodeficiency virusSystem infectionCryptococcal meningitisNeurological manifestationsCryptococcus neoformansRecurrent cerebral infarctionSevere neurological disabilityC. neoformans infectionUnusual clinical presentationUnusual neurological manifestationsDetailed clinical descriptionMagnetic resonance imagingOphthalmic zosterCryptococcal infectionCerebral infarctionImmunocompetent patientsNeoformans infectionNeurological disabilityClinical presentationHodgkin's diseaseImmunodeficiency syndromeImmunocompetent hostsImmunodeficiency virusCSF analysis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply